^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Angiopoietin 2 inhibitor

    Related drugs:
    4d
    Diabetic Macular Edema (DME) Patient Response to Faricimab and Associated Aqueous Humor Proteomic Differences Pre- and Post-Treatment (ChiCTR2500113982)
    P=N/A, N=154, Not yet recruiting, Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital
    New trial
    1m
    VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)
    P=N/A, N=6000, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Mar 2027
    Enrollment closed • Trial primary completion date • Real-world evidence
    |
    Lucentis (ranibizumab)
    2ms
    SHort Of Pace - Heart Failure (SHOP-HF) (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Fundación para la Investigación del Hospital Clínico de Valencia | Not yet recruiting --> Recruiting
    Enrollment open
    |
    L1-10
    2ms
    M-VIVA: Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting (clinicaltrials.gov)
    P=N/A, N=117, Recruiting, Singapore National Eye Centre
    New trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Lucentis (ranibizumab)
    3ms
    Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Nov 2027 --> Nov 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date • HEOR • Real-world evidence
    3ms
    CONSTANCE: A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P4, N=274, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Jan 2028 --> Sep 2027 | Trial primary completion date: Feb 2027 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    3ms
    A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=62, Terminated, Eli Lilly and Company | N=105 --> 62 | Completed --> Terminated
    Enrollment change • Trial termination
    |
    paclitaxel • Cyramza (ramucirumab) • zansecimab (LY3127804)
    4ms
    Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration (clinicaltrials.gov)
    P4, N=40, Recruiting, Hospital Authority, Hong Kong | Not yet recruiting --> Recruiting
    Enrollment open
    6ms
    A prospective study to evaluate the alterations of early macular microcirculation following intravitreal injection of faricimab for macular edema secondary to branch retinal vein occlusion (ChiCTR2500106303)
    P4, N=44, Not yet recruiting, The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University
    New P4 trial
    7ms
    Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration (clinicaltrials.gov)
    P4, N=40, Not yet recruiting, Hospital Authority, Hong Kong | Initiation date: Feb 2025 --> Jul 2025 | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial initiation date • Trial primary completion date
    7ms
    POYANG: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov)
    P3, N=280, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lucentis (ranibizumab)
    7ms
    Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=59, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Dec 2024 | Trial primary completion date: Feb 2026 --> Dec 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Keytruda (pembrolizumab) • trebananib (AMG 386)